Publications by authors named "S Hersch"
Objective: The Clarity AD phase III trial showed that lecanemab reduced amyloid markers in early Alzheimer's disease (AD) and resulted in less decline on measures of cognition and function than placebo. Herein, we aimed to characterize amyloid-β (Aβ) protofibril (PF) captured by lecanemab in human cerebrospinal fluid (CSF) from living participants with different stages in AD, which enable an enhanced understanding of the dynamic changes of lecanemab-associated Aβ-PF (Lec-PF) in vivo.
Methods: We newly developed a unique and highly sensitive immunoassay method using lecanemab that selectively captures Lec-PF.
Article Synopsis
- Alzheimer disease (AD) is a significant global health issue, and Lecanemab, an FDA-approved treatment for early AD, targets toxic Aβ protofibrils to improve patient outcomes.* -
- The Clarity AD study was an 18-month, double-blind trial that evaluated Lecanemab's safety and efficacy, involving nearly 2,000 participants with early AD.* -
- Results indicated that Lecanemab was generally well-tolerated, with some adverse events like infusion reactions and amyloid-related imaging abnormalities, and a total of 24 deaths observed, with a few linked to the treatment.*
Manufacturing DNA in yields higher-fidelity DNA than enzymatic synthesis.
Mol Ther Methods Clin Dev
June 2024
Biotechnologies such as gene therapy have brought DNA vectors to the forefront of pharmaceuticals. The quality of starting material plays a pivotal role in determining final product quality. Here, we examined the fidelity of DNA replication using enzymatic methods () compared to plasmid DNA produced in .
View Article and Find Full Text PDFArticle Synopsis
- - Lecanemab, a monoclonal antibody targeting amyloid-beta, showed significant promise in reducing cognitive decline in early Alzheimer's disease, as evidenced by 18-month phase 3 trial results.
- - In the Clarity AD trial, health-related quality-of-life (HRQoL) measurements indicated that participants receiving lecanemab experienced 49% to 56% less decline in quality of life compared to those on placebo.
- - Caregiver burden also decreased, with a 38% lower increase in strain for those caring for patients treated with lecanemab, highlighting its potential benefits for both patients and caregivers.